← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
51	51 Capricor Therapeutics CAPR $383M	169	-8	-5%	$942M
52	52 Regenxbio RGNX $454M	165	-13	-7%	$505M
53	53 MeiraGTx Holdings MGTX $904M	158	+25	+19%	$1.07B
54	54 Personalis PSNL $1.7B	158	+18	+13%	$1.14B
55	55 4D Molecular Therapeutics FDMT $674M	157	+4	+3%	$771M
56	56 Fate Therapeutics FATE $232M	156	-2	-1%	$193M
57	57 Solid Biosciences SLDB $585M	156	+6	+4%	$1.14B
58	58 Atrium Therapeutics RNA $131M	154	-9	-6%	$193M
59	59 Ocugen OCGN $285M	147	+10	+7%	$222M
60	60 Standard BioTools LAB $248M	143	-13	-8%	$244M
61	61 Fulgent Genetics FLGT $578M	141	-17	-11%	$322M
62	62 Lexeo Therapeutics LXEO $216M	141	+2	+1%	$411M
63	63 Quantum-Si Incorporated QSI $304M	141	-16	-10%	$46.8M
64	64 Cabaletta Bio CABA $275M	139	+31	+29%	$490M
65	65 Candel Therapeutics CADL $694M	137	+23	+20%	$519M
66	66 Caribou Biosciences CRBU $49.3M	137	0	0%	$84.8M
67	67 Design Therapeutics DSGN $609M	136	+11	+9%	$626M
68	68 Nkarta NKTX $145M	135	+9	+7%	$168M
69	69 Voyager Therapeutics VYGR $124M	135	0	0%	$123M
70	70 Lineage Cell Therapeutics LCTX $232M	132	+2	+2%	$153M
71	71 OmniAb OABI $662M	131	+3	+2%	$144M
72	72 Abeona Therapeutics ABEO $249M	126	+18	+17%	$243M
73	73 MaxCyte MXCT $129M	122	-9	-7%	$78M
74	74 Kyverna Therapeutics KYTX $351M	120	+9	+8%	$335M
75	75 Neurogene NGNE $444M	111	+15	+16%	$544M